Maryam Hatami1, Mohammad Reza Sobhan2, Seyed Alireza Dastgheib3, Mohammad Hossein Jarahzadeh1, Mohammadali Jafari4, Amirhossein Yadegari5, Jalal Sadeghizadeh-Yazdi6, Hossein Neamatzadeh7,8. 1. Department of Anesthesiology and Critical Care, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. 2. Department of Orthopedics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. 3. Department of Medical Genetics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. 4. Department of Emergency Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. 5. Medical Student, Shahid Sadoughi Hospital, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. 6. Department of Food Science and Technology, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. 7. Mother and Newborn Health Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. 8. Department of Medical Genetics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Abstract
BACKGROUND: Several lines of research have suggested that the 472G > A (Val158Met) polymorphism at Catechol-O-methyltranferase (COMT) gene is implicated in the pathophysiology of FMS. Here, we have evaluated the association of COMT 472G > A polymorphism with risk of FMS. METHODS: In this study 250 patients with FMS and 250 healthy controls were evaluated for COMT 472G > A polymorphism by RFLP-PCR assay. RESULTS: There were no significant differences in the allele and genotype frequencies of COMT 472G > A polymorphism between FMS cases and healthy controls. CONCLUSIONS: Our results suggested that the COMT 472G > A polymorphism may not be risk factor for development of FMS.
BACKGROUND: Several lines of research have suggested that the 472G > A (Val158Met) polymorphism at Catechol-O-methyltranferase (COMT) gene is implicated in the pathophysiology of FMS. Here, we have evaluated the association of COMT 472G > A polymorphism with risk of FMS. METHODS: In this study 250 patients with FMS and 250 healthy controls were evaluated for COMT 472G > A polymorphism by RFLP-PCR assay. RESULTS: There were no significant differences in the allele and genotype frequencies of COMT 472G > A polymorphism between FMS cases and healthy controls. CONCLUSIONS: Our results suggested that the COMT 472G > A polymorphism may not be risk factor for development of FMS.
Authors: Andrea Gail Nackley; Kai Soo Tan; Karamarie Fecho; Patrick Flood; Luda Diatchenko; William Maixner Journal: Pain Date: 2006-11-07 Impact factor: 7.926